There is much more money available for biopharma and life sciences in Europe than there was almost two decades ago.” And yet most early-stage founders are finding it harder than ever to raise.
To many executives and investors, the start of 2026 felt like a new dawn. A multi-year pullback finally eased in late 2025, as a wave of dealmaking, financings and positive clinical readouts revitalised investor interest and generalist money began tiptoeing back into the sector. But the capital is not flowing evenly. Beneath the headline optimism, 2026 is shaping up as a market split firmly into haves and have-nots: abundant funding for de-risked, differentiated assets, and a steepening climb for everyone else.
Below, we break down the five trends defining biotech financing this year, and, crucially, what each one means for pricing, reimbursement and market access strategy.
Biotech Financing at a Glance: Q1 2026
| Metric | Q1 2026 | Comparison | Source |
|---|---|---|---|
| Seed & Series A (first-time financings) | 50 deals, ~$2.3B | Down from 60 deals / $3.7B in Q1 2025 | J.P. Morgan / Fierce Biotech |
| Biopharma IPOs | 6 IPOs, ~$1.8B raised | Already above full-year 2025 proceeds | J.P. Morgan |
| Median IPO size | ~$287.5M | Highest of any quarter since 2021 | BioPharma Dive |
| Biopharma M&A | $15.6B across 19 deals | Part of a record 2025 (+133% YoY) | J.P. Morgan / Value The Markets |
| US vs European VC | US ~£7.6B vs Europe £893M | Europe down from £1.8B in Q4 2025 | UK BioIndustry Association |
1. A market increasingly divided between the haves and the have-nots
The single defining feature of 2026 is selectivity. According to J.P. Morgan’s first-quarter report, investors backed just 50 seed and Series A rounds worth a combined $2.3 billion in the first three months of the year, down from 60 rounds worth $3.7 billion in the same period of 2025, putting first-time financings tracking below their recent post-pandemic pace.
Where money is moving, it is concentrating. Across the broader market, follow-on rounds now dominate: investors are reinforcing companies they already back rather than funding new formation, and a handful of large platform financings account for the lion’s share of capital deployed. Big early bets still happen (Slate Medicine pulled in $130 million and Poplar Therapeutics around $95 million), but they are the exceptions that prove the rule.
The result is the “have and have-nots” dynamic that CFOs flagged throughout 2025: companies with strong clinical or commercial traction thrive, while those still building their evidence base face a higher bar to secure investor attention and terms.
2. The IPO Window Cracks Open, But Only for the Few
After a long drought, the public markets are reopening. Six biopharma IPOs raised roughly $1.8 billion in Q1 2026, already surpassing the full-year 2025 total, and the median raise of about $287.5 million was the highest of any quarter since 2021.
But the number of offerings has barely moved. The cheques are simply bigger, later-stage and reserved for differentiated science. Obesity developer Kailera Therapeutics priced the largest biotech IPO in Nasdaq history, raising around $625 million at pricing (about $719 million once the over-allotment was exercised). Aktis Oncology opened the year’s class with a $318 million debut, followed by Generate Biomedicines (~$400M), Eikon Therapeutics (~$381M), Veradermics (~$295M) and Alamar Biosciences (~$220M).
The reception, however, has been selective and stricter than the last cycle: several debutants, including Eikon and Generate, slipped below their offer price. Analysts project only 30 to 35 biotech IPOs for the full year, and Nasdaq remains the venue of choice even for European companies seeking deeper capital pools.
3. AI’s Gravitational Pull on Capital
Biotech is not raising in a vacuum. It is competing with artificial intelligence for every available dollar. Around 80% of global venture capital in Q1 2026 flowed to AI companies, with four mega-deals accounting for more than $188 billion of a record $300 billion quarter. That gravitational pull has squeezed attention and capital away from non-AI sectors.
The twist is that AI is also reshaping biotech from the inside. The platform companies attracting the largest cheques, such as Generate Biomedicines’ protein design engine and Eikon’s single-molecule tracking platform, sit squarely at the intersection of AI and drug discovery, and experts increasingly point to AI as a driving force behind the IPO resurgence. For founders, this cuts both ways: a credible AI-enabled discovery story can unlock capital, but a “me-too” platform now struggles to stand out.
4. The Transatlantic Gap Widens
The structural divide between US and European financing is widening, not closing. In Q1 2026, US biotechs raised roughly £7.6 billion against just £893 million across Europe, itself down from £1.8 billion in Q4 2025. The UK remained Europe’s largest venture market at £516 million, but the depth gap is stark, and a striking 66 of 67 EU-based biotechs that went public over the past six years did so outside the EU.
Europe is responding. Heavyweight investors including Novo Holdings and Sofinnova Partners have launched the European Life Sciences Coalition to lobby for stronger continental financing, Paris-based Kurma Partners closed its €215 million Biofund IV (backed by CSL, the European Investment Fund and Bpifrance), and Milan’s AAVantgarde secured a $141 million Series B for rare-disease gene therapies. The capital exists, but later-stage, scale-up funding remains Europe’s persistent bottleneck.
5. M&A and the Patent Cliff: The Exit Engine and the Financing Backstop
Financing confidence in 2026 rests heavily on the exit environment, and dealmaking is roaring. Aggregate biopharma M&A more than doubled in 2025, rising 133% to $133 billion (the highest deal count since 2021), and momentum carried into 2026, with seven billion-dollar transactions worth a combined $29 billion closing in a single 12-day window in March.
The engine behind this is the patent cliff: large pharma faces around $300 billion in revenue at risk from losses of exclusivity by 2030, and industry analysts predict 20-plus acquisitions over $1 billion in 2026 alone. Two cautions temper the picture: the BIOSECURE Act, passed in late 2025, adds friction to deals involving Chinese-derived assets, and some analysts warn that bloated valuations and crowding into hot therapeutic areas could deflate quickly on negative readouts. Still, for the right asset, M&A is both the dominant exit and the backstop that underwrites venture conviction.
6. What Biotechs Can Do to Land on the Right Side of the Divide
The trends above describe the market biotechs are raising into, not a verdict on any individual company. Selectivity cuts both ways: the same investors tightening their criteria are actively competing for assets that can show a credible, reimbursed commercial future. The encouraging news is that much of what moves a company onto the right side of the divide is within its own control, and a focused set of high-impact activities matters far more than an exhaustive, big-pharma-style programme. Even biotechs that intend to out-license or partner need to drive these activities themselves: a partner or acquirer will not retrofit a market access story that was never started, and the companies that reach their market access value inflection point are consistently the ones that improve both their valuation and their odds of closing a deal.
Start with what payers actually value. Before designing pivotal trials, understand how your priority markets judge value, because their criteria differ in ways that directly shape evidence needs: Germany centres its assessment on added clinical benefit, while the UK weighs cost-effectiveness heavily. Rather than a broad-brush push across every geography, a targeted approach to a few key markets and market archetypes is usually enough to surface the comparator, endpoint and evidence choices that determine reimbursement potential later. Comparator and endpoint decisions locked in at trial design are among the hardest to undo, and the EU Joint Clinical Assessment has raised the stakes on getting them right early.
Build a stage-appropriate market access plan. A market access plan should scale with the asset, not balloon ahead of it. For a pre-clinical programme, a concise one-page roadmap of strategic goals and key activities can be enough; as a product advances, the plan should map country-specific activities, payer engagement, pricing and reimbursement scenarios and submission timelines. The discipline that distinguishes the strongest companies is simply revisiting and tracking that plan as the science and the financing picture evolve.
Do not miss out on reimbursed early access programs / named patient programs. Assets responding to an unmet medical need with no viable therapeutic alternative are frequently eligible for reimbursed early access ahead of Marketing Authorization, sometimes from phase 1 onwards. This can drive a win-win-win, patients get access to much needed therapies earlier, biotechs can realize early revenue to fund ongoing clinical development and payers get additional real-world evidence complementing the RCT data. For some companies early access revenue can replace a funding round and represent a source of significant funding.
Get to a defensible pricing range early, without over-engineering it. Investors and prospective partners weigh market access readiness heavily in diligence, so a high-level pricing assessment, anchored in the target product profile and grounded in real payer feedback, is worth far more than an elaborate, “gold-plated” model at this stage. Focused research with a handful of payers and experts per priority market, or a single well-run advisory board, is typically enough to establish a credible range and identify the value drivers that resonate. Your counterparts are generating this insight regardless; producing it yourself closes an information asymmetry rather than leaving value on the table. This is particularly needed in the new MFN-era where companies able to outline an MFN-compatible global pricing strategy have a competitive advantage.
Put the payer story into the investor narrative. In a have-and-have-nots market, the pitch deck is where many biotechs quietly lose ground: too many still include little or no detail on pricing and reimbursement potential, and sophisticated investors notice the gap immediately. A concise synthesis of the clinical and economic burden of disease, paired with a pricing range built on early payer feedback and a clearly explained rationale, turns a promising scientific story into a financeable one, and signals exactly the commercial discipline that today’s capital is looking for.
⚠️ What This Means for Market Access Strategy
Behind every one of these trends sits the same shift: investors and acquirers are now pricing in commercial and reimbursement risk far earlier than they used to. Three developments make market access central to the financing conversation in 2026.
The US is no longer a global “price safety net.” With Most-Favored-Nation agreements and CMS international-reference pricing models now live, ex-US pricing decisions can feed back into US price. Valuation models that once estimated ex-US sales as a simple percentage of US value are no longer viable. Deal teams now demand country-level pricing and MFN-risk assessment, and in high-delta categories such as immunology, reference-pricing exposure can materially lower the value of ex-US rights.
Evidence expectations have hardened. The EU Joint Clinical Assessment, in effect since 2025, is reshaping how biotechs must generate evidence for European access. Comparator and endpoint choices locked in during trial design now determine reimbursement potential, and therefore asset value, long before a partner or acquirer is at the table.
Price reform has moved from theory to reality. With IRA negotiated prices becoming observable market reality in 2026, the signal to investors is unambiguous: a compelling clinical story is no longer enough on its own.
The throughline for founders is simple. In a have-and-have-nots market, the assets that attract capital and command premium deal terms are those that can demonstrate a credible, reimbursed commercial future, not just promising science. A defensible payer value proposition has become part of the financing narrative itself.
The Bottom Line
2026 is a market of conviction, not breadth. Capital is plentiful for de-risked, differentiated assets with a clear path to reimbursed commercial value, and scarce for almost everything else. For biotechs raising now, or preparing to exit, the decisive differentiator is increasingly the strength of the commercial and market access case standing behind the science.
Ready to Strengthen the Market Access Case Behind Your Raise?
Justin Stindt Consultants helps biotech companies turn scientific promise into a credible, reimbursed commercial narrative, the kind investors and partners now expect to see. From directional pricing and reimbursement assessments and HTA engagement to payer value propositions and due-diligence-ready market access packages, our team supports biotechs at every stage of the financing and partnering journey.
Contact our experts at jstindt.com/contact-us for a tailored consultation.
